**Supplementary Table 1: Comparison of Hereditary Hemorrhagic Telangiectasia Patients with and without Liver Imaging\***

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **All Cases** **(N=45)** | **Liver Imaging (N=25)** | **No Liver Imaging****(N=20)** | **P**† |
| Age, years | 52.7 ± 15.4 | 55.3 ± 14.8 | 49.5 ± 15.9 | 0.22 |
| Female sex, % | 68.9 | 68.0 | 70.0 | 1.00 |
| Curacao criteria, %EpistaxisAVMTelangiectasiasFamily history | 97.871.188.988.9 | 96.072.088.088.0 | 100.070.090.090.0 | 1.001.001.001.00 |
| HHT genetic mutation, %*ACVRL1**ENG**SMAD4* | 48.920.02.2 | 52.020.00.0 | 45.020.05.0 | 0.83 |
| Elevated ammonia level, % | 40.0 | 52.0 | 25.0 | 0.07 |
| Non-HHT liver disease, %SteatosisCirrhosis | 4.42.2 | 4.04.0 | 5.00.0 | 1.00 |
| ALT, U/L | 23.9 ± 13.9 | 25.7 ± 16.3 | 21.7 ± 9.9 | 0.34 |
| AST, U/L | 28.0 ± 17.8 | 31.0 ± 21.9 | 24.3 ± 10.1 | 0.21 |
| Total bilirubin, mg/dL | 0.5 ± 0.3 | 0.5 ± 0.4 | 0.4 ± 0.3 | 0.21 |
| Alkaline phosphatase, U/L | 84.6 ± 37.2 | 89.9 ± 43.6 | 78.0 ± 26.9 | 0.29 |

\* Plus-minus values are means ± SD. AVM denotes arteriovenous malformation; *ACVRL1*, activin receptor-like kinase 1; *ENG*, endoglin; *SMAD4*, SMAD family member 4, HHT hereditary hemorrhagic telangiectasia, ALT alanine transaminase, AST aspartate transaminase, GI gastrointestinal.

† Comparing patients with and without available liver imaging.